Harvard Bioscience - HBIO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.08
▼ -0.02 (-0.95%)

This chart shows the closing price for HBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Harvard Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HBIO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Harvard Bioscience in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.08.

This chart shows the closing price for HBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Harvard Bioscience. This rating has held steady since March 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/26/2023BenchmarkBoost Target$4.00 ➝ $7.00
3/10/2023BenchmarkBoost TargetSpeculative Buy ➝ Buy$3.00 ➝ $4.00
11/15/2022BenchmarkLower Target$3.00
11/9/2022KeyCorpLower TargetOverweight$7.00 ➝ $5.00
8/5/2022KeyCorpLower TargetOverweight$10.00 ➝ $7.00
3/10/2021KeyCorpBoost Target$6.00 ➝ $9.00
1/7/2021BenchmarkUpgradeSpeculative Buy ➝ Buy
12/9/2020Northland SecuritiesInitiated CoverageOutperform
11/9/2020KeyCorpInitiated CoverageOverweight
2/27/2020BenchmarkBoost TargetSpeculative Buy$3.50 ➝ $4.00
(Data available from 12/26/2019 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 18 positive mentions
  • 11 negative mentions
  • 5 very negative mentions
5/30/2024
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2024
  • 3 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
7/29/2024
  • 7 very positive mentions
  • 15 positive mentions
  • 7 negative mentions
  • 5 very negative mentions
8/28/2024
  • 4 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/27/2024
  • 3 very positive mentions
  • 24 positive mentions
  • 9 negative mentions
  • 3 very negative mentions
10/27/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/26/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2024

Current Sentiment

  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Harvard Bioscience logo
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Read More

Today's Range

Now: $2.08
Low: $2.05
High: $2.11

50 Day Range

MA: $2.27
Low: $2.03
High: $2.82

52 Week Range

Now: $2.08
Low: $1.99
High: $5.56

Volume

80,119 shs

Average Volume

123,574 shs

Market Capitalization

$90.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Harvard Bioscience?

The following Wall Street analysts have issued reports on Harvard Bioscience in the last twelve months: StockNews.com.
View the latest analyst ratings for HBIO.

What is the current price target for Harvard Bioscience?

0 Wall Street analysts have set twelve-month price targets for Harvard Bioscience in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Harvard Bioscience in the next year.
View the latest price targets for HBIO.

What is the current consensus analyst rating for Harvard Bioscience?

Harvard Bioscience currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HBIO.

What other companies compete with Harvard Bioscience?

How do I contact Harvard Bioscience's investor relations team?

Harvard Bioscience's physical mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The medical instruments supplier's listed phone number is (508) 893-8999 and its investor relations email address is [email protected]. The official website for Harvard Bioscience is www.harvardbioscience.com. Learn More about contacing Harvard Bioscience investor relations.